Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

Although the BRAF inhibitors dabrafenib and vemurafenib have both proven successful against BRAF‐mutant melanoma, there seem to be differences in their mechanisms of action. Here, we show that dabrafenib is more effective at inhibiting the growth of NRAS‐mutant and KRAS‐mutant cancer cell lines than...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Phadke, Manali, Remsing Rix, Lily L., Smalley, Inna, Bryant, Annamarie T., Luo, Yunting, Lawrence, Harshani R., Schaible, Braydon J., Chen, Yian A., Rix, Uwe, Smalley, Keiran S. M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5748485/
https://ncbi.nlm.nih.gov/pubmed/29112787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12152
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados